Arcosa Inc. (ACA)

Tariffs, inflation and housing headwinds weigh on the industry. Yet, AWI, FTDR, ACA and ECG look primed to benefit from infrastructure and innovation tailwinds.

Oscar Health, an ACA marketplace pure play, is leading the way.

Arcosa remains a soft 'buy' due to attractive valuation, ongoing revenue growth, and solid industry catalysts despite recent underperformance vs. the S&P 500. ACA's revenue growth is driven by strateg...

Oscar Health (OSCR) remains up 31% YTD as investors watch for developments on ACA enhanced subsidies, a key driver for its marketplace business. Policy risk looms with potential ACA subsidy expiration...

DALLAS--(BUSINESS WIRE)--Arcosa, Inc. (NYSE: ACA), a provider of infrastructure-related products and solutions, announced today the dual listing of its common stock on NYSE Texas, the newly launched f...

DALLAS--(BUSINESS WIRE)--Arcosa, Inc. (NYSE: ACA) (“Arcosa” or the “Company”), a provider of infrastructure-related products and solutions, today announced that its Board of Directors has declared a r...

Oscar Health is deeply undervalued but faces high short-term uncertainty due to ACA-specific risks and sector-wide negative catalysts. The expiration of ACA subsidies, adverse selection, and new legis...

Arcosa, Inc. (NYSE:ACA ) Q2 2025 Earnings Conference Call August 8, 2025 8:30 AM ET Company Participants Antonio Carrillo - President, CEO & Director Erin Drabek - VP of Investor Relations Gail M. Pec...

Arcosa (ACA) Q2 EPS Jumps 40%

Arcosa (ACA) came out with quarterly earnings of $1.27 per share, beating the Zacks Consensus Estimate of $1.05 per share. This compares to earnings of $0.91 per share a year ago.